• The DX Stocks are jointly selected by METI, TSE and IPA to accelerate digital transformation of Japanese companies
• Selected as a “DX Platinum Companies 2023-2025,” granted to companies that have continued outstanding DX implementation since the start of the program
• Chugai is the only company in the pharmaceutical industry which has been listed among the DX Stocks for four consecutive years

TOKYO, June 1, 2023 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it is selected as a “DX Platinum Companies 2023-2025” in Digital Transformation Stocks (DX Stocks) 2023 elected by the Ministry of Economy, Trade and Industry (METI), the Tokyo Stock Exchange (TSE) and the Information-technology Promotion Agency, Japan (IPA). From among TSE-listed companies, “DX Stocks” are designated to those companies, in each industrial category, that have established internal systems to promote digital transformation (DX) leading to increased corporate value, and have outstanding achievements in digital utilization. Chugai has been selected as a DX Stock for four consecutive years and selected as a “DX Platinum Companies 2023-2025,” granted to companies that have continued especially outstanding DX implementation since the start of the program.

DX Stock companies are selected from TSE-listed companies, in consideration of contribution to corporate value, and capability of DX realization. Chugai was selected as a “DX Platinum Companies 2023-2025” based on recognition as a DX Stock for three consecutive years, acquisition of DX Grand Prix 2022 and the review by the Stock Evaluation Committee.

“We are very honored to be selected as a Platinum Company. Last year, we made a lot of progress, such as advancing AI drug discovery, filing for regulatory approval with RWD, promoting Decentralized Clinical Trial (DCT), starting initiatives for Web3.0, and operating digital plant at the Ukima Plant,” said Chugai’s Executive Vice President and Head of Digital Transformation Unit, Satoko Shisai. “We’re right on track to work toward the Phase 2 (Change our business) and the Phase 3 (Change society), which are described in our roadmap for 2030 “CHUGAI DIGITAL VISION 2030.” This year, we also start joining the program initiated by Roche to renewal ERP platform, and we will work to create outcomes by further accelerating Digital and IT strategies.”

In order to realize its goal of becoming a top innovator in the healthcare industry, Chugai formulated a growth strategy “TOP I 2030,” which is consisted of two pillars of “global first-class drug discovery” and a “futuristic business model.” DX is positioned as one of the key drivers to achieve the target. In accelerating DX, Chugai is committed to transforming its business and providing healthcare solutions that will change society through three basic strategies of “CHUGAI DIGITAL VISION 2030”: 1) Strengthen the digital platform, 2) Optimize all value chains, and 3) Digital transformation for drug discovery and development.

[Criteria for DX Platinum Company]

1. Companies that meet the following requirements
   • Selected as a DX Stock for three consecutive years
   • Selected as a DX Grand Prix in the past
2. Evaluation by the Stock Evaluation Committee

* The period of selection shall be three years.

[References]
CHUGAI DIGITAL website
https://www.chugai-pharm.co.jp/english/profile/digital/

CHUGAI DIGITAL official note (in Japanese only)
https://note.chugai-pharm.co.jp/